Zolacabtagene autoleucel

Highest phase reached

Phase 1

Drug type

Gene

bms 986353
bms 986353 is an investigational cd19 targeted car t cell product the cd19 specific car consists of a single chain variable fragment scfv binding domain derived from a cd19 specific monoclonal antibody mab fmc63 an igg derived hinge region a cd28 transmembrane domain and the cd137 41bb and cd3ζ chain signaling domains the third generation sin lentiviral vector which encodes the car domains described above also encodes a truncated human epidermal growth factor receptor egfrt that is expressed separately from the cd19 car on the t cell surface
BMS-986353
BMS-986353 is an investigational CD19-targeted CAR T-cell product. The CD19-specific CAR consists of a single-chain variable fragment (scFv) binding domain derived from a CD19-specific monoclonal antibody (mAb; FMC63), an IgG-derived hinge region, a CD28 transmembrane domain, and the CD137 (41BB) and CD3ζ chain signaling domains. The third-generation SIN lentiviral vector, which encodes the CAR domains described above, also encodes a truncated human epidermal growth factor receptor (EGFRt) that is expressed separately from the CD19 CAR on the T cell surface
cc 97540
CC 97540 [WHO-DD]
cc 97540 who dd
CC-97540
CC-97540 (BMS-986353)
zolacabtagene autoleucel
Zolacabtagene autoleucel
ZOLACABTAGENE AUTOLEUCEL [USAN]
zolacabtagene autoleucel usan

FDA ingredient codes (UNII)

Related records

A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)